NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CATX

Perspective Therapeutics Inc

Jul 03 • 04:00PM ET

3.68

Dollar change +0.29
Percentage change 8.55	%

Healthcare • Medical Devices • USA • AMEX

Peers: TGTX KPTI AVXL IMUX XOMA CLPT CYCN ONCT KALA MNOV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.21	Insider Own	27.07%	Shs Outstand	74.05M	Perf Week	1.66%
Market Cap	273.16M	Forward P/E	-	EPS next Y	-1.29	Insider Trans	0.72%	Shs Float	54.14M	Perf Month	19.09%
Enterprise Value	65.28M	PEG	-	EPS next Q	-0.29	Inst Own	65.42%	Short Float	10.37%	Perf Quarter	79.51%
Income	-85.17M	P/S	185.82	EPS this Y	6.46%	Inst Trans	-4.09%	Short Ratio	4.85	Perf Half Y	20.26%
Sales	1.47M	P/B	0.96	EPS next Y	-12.06%	ROA	-27.87%	Short Interest	5.62M	Perf YTD	15.36%
Book/sh	3.84	P/C	1.29	EPS next 5Y	-1.94%	ROE	-32.92%	52W High	16.55 -77.76%	Perf Year	-67.14%
Cash/sh	2.85	P/FCF	-	EPS past 3/5Y	-55.62% -9.86%	ROIC	-29.63%	52W Low	1.60 130.00%	Perf 3Y	34.26%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-47.51% -27.61%	Gross Margin	-82.32%	Volatility	9.79% 11.65%	Perf 5Y	-36.75%
Dividend TTM	-	EV/Sales	44.41	EPS Y/Y TTM	-30.27%	Oper. Margin	-5140.99%	ATR (14)	0.37	Perf 10Y	-76.10%
Dividend Ex-Date	-	Quick Ratio	17.02	Sales Y/Y TTM	-	Profit Margin	-5790.07%	RSI (14)	57.83	Recom	1.14
Dividend Gr. 3/5Y	- -	Current Ratio	17.02	EPS Q/Q	-1.25%	SMA20	5.55%	Beta	1.18	Target Price	14.11
Payout	-	Debt/Eq	0.01	Sales Q/Q	5.23%	SMA50	26.85%	Rel Volume	0.44	Prev Close	3.39
Employees	140	LT Debt/Eq	0.01	Earnings	May 12 AMC	SMA200	-27.70%	Avg Volume	1.16M	Price	3.68
IPO	Nov 10, 2005	Option/Short	Yes / Yes	EPS/Sales Surpr.	17.93% 140.00%	Trades		Volume	511,203	Change	8.55%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-25	Initiated	H.C. Wainwright	Buy	$10
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$15
Nov-25-24	Downgrade	BofA Securities	Buy → Neutral	$24 → $5
Oct-24-24	Initiated	UBS	Buy	$20
Oct-01-24	Initiated	Wedbush	Outperform	$25
Sep-25-24	Initiated	Truist	Buy	$21
Jul-25-24	Initiated	BofA Securities	Buy	$24
May-09-24	Initiated	Cantor Fitzgerald	Overweight

Jun-24-25 12:52PM	Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices (PR Newswire) -7.06%
Jun-21-25 08:00AM	Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting (GlobeNewswire)
08:00AM	Perspective Therapeutics Commences Recruitment for [212Pb]VMT-a-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial (GlobeNewswire)
08:00AM	Perspective Therapeutics Commences Recruitment for [212Pb]VMT--NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial (GlobeNewswire)
Jun-18-25 11:19AM	Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going (PR Newswire)
05:21PM	Loading…
May-30-25 05:21PM	Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the 2025 ASCO Annual Meeting (GlobeNewswire) -7.00%
05:21PM	Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT--NET at the 2025 ASCO Annual Meeting (GlobeNewswire)
May-21-25 11:22AM	Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential (Insider Monkey) -13.07%
May-12-25 04:43PM	Perspective Therapeutics: Q1 Earnings Snapshot (Associated Press Finance) +6.81%
04:36PM	Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results (GlobeNewswire)
May-01-25 07:00AM	Perspective Therapeutics to Participate in Upcoming May Investor Conferences (GlobeNewswire)
Apr-29-25 07:00AM	Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-a Positive Solid Tumors (GlobeNewswire)
07:00AM	Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP- Positive Solid Tumors (GlobeNewswire)
Apr-23-25 12:25PM	Perspective Therapeutics Announces Acceptance of VMT-a-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting (GlobeNewswire) +8.88%
12:25PM	Perspective Therapeutics Announces Acceptance of VMT- -NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting (GlobeNewswire)
07:00AM	Loading…
07:00AM	Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last? (Zacks)
Apr-17-25 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results (GlobeNewswire)
Apr-11-25 07:00AM	Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma (GlobeNewswire)
Apr-09-25 12:08AM	Is Now The Time To Invest In Perspective Therapeutics (Seeking Alpha) +11.11%
Apr-02-25 09:35AM	Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround (Zacks)
Mar-31-25 07:00AM	Perspective Therapeutics to Participate in Upcoming April Investor Conferences (GlobeNewswire)
Mar-26-25 04:10PM	Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results (GlobeNewswire) -8.10%
Mar-17-25 07:00AM	Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma (GlobeNewswire)
Feb-26-25 07:00AM	Perspective Therapeutics to Present at Upcoming March Investor Conferences (GlobeNewswire)
Feb-21-25 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results (GlobeNewswire)
Feb-05-25 07:00AM	Perspective Therapeutics to Participate in Upcoming February Investor Conferences (GlobeNewswire) +5.67%
Jan-24-25 12:18PM	Perspective Therapeutics Touts Encouraging Updated Data From Gastrointestinal Cancer Trial, Stock Soars (Benzinga) +10.47%
07:00AM	Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
07:00AM	Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT- -NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Jan-22-25 07:00AM	Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025 (GlobeNewswire)
07:00AM	Loading…
07:00AM	Perspective Therapeutics to Discuss Data on [212Pb]VMT- -NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025 (GlobeNewswire)
Jan-14-25 08:35AM	Perspective Therapeutics provides business updates, strategic priorities (TipRanks) -5.88%
Jan-13-25 08:00AM	Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-10-25 07:00AM	Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-06-25 08:00AM	Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer (GlobeNewswire)
Nov-27-24 07:00AM	Perspective Therapeutics to Participate in Upcoming Investor Conferences in December (GlobeNewswire) -6.36%
Nov-26-24 07:00AM	Perspective Therapeutics price target lowered to $16 from $25 at RBC Capital (TipRanks) +19.24%
06:45AM	Perspective Therapeutics downgraded to Neutral from Buy at BofA (TipRanks)
Nov-21-24 07:15AM	Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium (GlobeNewswire) -51.38%
07:15AM	Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT- -NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium (GlobeNewswire)
Nov-16-24 01:26AM	Is Perspective Therapeutics (CATX) the Best Multibagger Stock to Buy Heading into 2025? (Insider Monkey)
Nov-15-24 04:08PM	Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024 (GlobeNewswire) -11.66% -11.68%
04:08PM	Perspective Therapeutics to Discuss Data on [212Pb]VMT- -NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024 (GlobeNewswire)
Nov-12-24 04:37PM	Perspective Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) -6.94%
04:05PM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results (GlobeNewswire)
Oct-31-24 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-29-24 07:00AM	Perspective Therapeutics to Participate in Upcoming Investor Conferences in November (GlobeNewswire)
Oct-23-24 07:00AM	Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire) -5.65%
Oct-16-24 07:00AM	Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey (GlobeNewswire)
Oct-12-24 10:18AM	Perspective Therapeutics, Inc (CATX): A Small-Cap Pioneer in Targeted Cancer Therapies (Insider Monkey)
Oct-11-24 08:30AM	Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research (GlobeNewswire)
Oct-10-24 05:14PM	Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research (GlobeNewswire)
Oct-07-24 07:00AM	Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day (GlobeNewswire)
Sep-30-24 07:00AM	Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire) +6.21%
Sep-10-24 07:00AM	Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024 (GlobeNewswire)
Sep-05-24 07:00AM	Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma (GlobeNewswire)
Aug-28-24 07:00AM	Perspective Therapeutics to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-13-24 09:40AM	Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year? (Zacks) +5.71%
Aug-12-24 04:35PM	Perspective Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results (GlobeNewswire)
Jul-30-24 07:00AM	Perspective Therapeutics to Participate at Upcoming Investor Conferences in August (GlobeNewswire)
Jul-25-24 06:15AM	3 Outperforming Stocks Surpassing Even Nvidia This Year (InvestorPlace) +6.24%
Jul-22-24 07:00AM	Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-16-24 09:55AM	Wall Street Analysts Think Perspective Therapeutics (CATX) Could Surge 80.31%: Read This Before Placing a Bet (Zacks)
Jun-12-24 07:00AM	Perspective Therapeutics Announces Inclusion in the Russell 3000 Index (GlobeNewswire) +5.56%
Jun-11-24 07:00AM	Perspective Therapeutics Announces 1-for-10 Reverse Stock Split (GlobeNewswire)
Jun-10-24 04:10PM	Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting (GlobeNewswire) +8.33%
May-24-24 08:01AM	Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
May-20-24 07:00AM	Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024 (GlobeNewswire)
May-15-24 07:49AM	Perspective Therapeutics Swings to Loss in Q1, Revenue Rises (MT Newswires) -10.80%
07:13AM	Perspective Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results (GlobeNewswire)
May-03-24 07:00AM	Perspective Therapeutics to Participate at Upcoming May Investor Conferences (GlobeNewswire)
03:04AM	Lantheus Holdings Inc (LNTH) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ... (GuruFocus.com)
May-02-24 07:00AM	Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results (GlobeNewswire)
Apr-30-24 07:00AM	Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-a-NET in NETs (GlobeNewswire)
07:00AM	Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT- -NET in NETs (GlobeNewswire)
Apr-08-24 08:00AM	Perspective Therapeutics to Participate at Upcoming April Investor Conferences (GlobeNewswire)
Mar-30-24 05:31AM	Perspective Therapeutics Inc (CATX) Reports Fiscal Year 2023 Financial Results (GuruFocus.com)
Mar-28-24 07:30AM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results (GlobeNewswire)
Mar-19-24 10:39AM	Heard on the Street: Pharma Goes Radioactive as AstraZeneca Announces Fusion Deal (The Wall Street Journal) +16.06%
Mar-18-24 08:00AM	Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma (GlobeNewswire) -9.81%
Mar-11-24 08:00AM	Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024 (GlobeNewswire)
Mar-05-24 08:00AM	Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility (GlobeNewswire)
Mar-04-24 09:45AM	Perspective Therapeutics Announces $87.4 Million Private Placement (GlobeNewswire) +11.72%
Feb-26-24 08:00AM	Perspective Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire) -6.25%
Feb-20-24 06:30AM	These Drug Companies Are Going Nuclear to Fight Cancer (The Wall Street Journal)
Feb-12-24 08:00AM	Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) -7.79%
Feb-08-24 10:00AM	Earnings Preview: Perspective Therapeutics (CATX) Q4 Earnings Expected to Decline (Zacks) -5.72%
Feb-01-24 08:00AM	Perspective Therapeutics Introduces Pre-Targeting Theranostic Technology Platform (GlobeNewswire)
Jan-22-24 04:05PM	Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement (GlobeNewswire)
Jan-18-24 07:00AM	Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement (GlobeNewswire) +26.12%
Jan-17-24 04:05PM	Perspective Therapeutics Announces Proposed Public Offering (GlobeNewswire)
08:00AM	Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT--NET and [(212)Pb]VMT01 (GlobeNewswire)
Jan-09-24 08:00AM	Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability (GlobeNewswire) +9.15%
08:00AM	Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics (GlobeNewswire)
Jan-05-24 08:00AM	Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment (GlobeNewswire) +8.77%
Jan-02-24 08:00AM	Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-23 08:00AM	Perspective Therapeutics Divests Brachytherapy Business (GlobeNewswire) -5.24%
Dec-07-23 08:00AM	Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT--NET to Treat Refractory or Relapsed Neuroendocrine Tumors (GlobeNewswire)

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Spoor Johan M.	Chief Executive Officer	Mar 28 '25	Buy	2.24	22,026	49,384	59,383	Apr 01 06:44 PM
Spoor Johan M.	Chief Executive Officer	Mar 28 '25	Buy	2.21	4,650	10,288	4,650	Apr 01 06:44 PM
Williamson Robert F III	Director	Mar 31 '25	Buy	2.14	38,145	81,775	108,982	Apr 01 05:04 PM
Williamson Robert F III	Director	Mar 28 '25	Buy	2.27	22,192	50,376	70,837	Apr 01 05:04 PM
Graham Juan	Chief Financial Officer	Mar 28 '25	Buy	2.25	33,333	74,946	35,354	Apr 01 05:03 PM
Woods Lori A	Director	Mar 31 '25	Buy	2.13	23,475	49,999	183,460	Apr 01 05:03 PM
HENSON HEIDI	Director	Dec 04 '24	Buy	3.85	25,975	100,004	25,975	Dec 06 04:05 PM
Spoor Johan M.	CEO	Dec 04 '24	Buy	3.77	8,000	30,132	36,257	Dec 04 05:20 PM
Williamson Robert F III	Director	Nov 25 '24	Buy	3.64	6,266	22,814	430,058	Nov 27 07:05 AM
Hunt Jonathan Robert	Chief Financial Officer	Nov 25 '24	Buy	3.82	12,829	48,974	48,800	Nov 27 07:00 AM
Spoor Johan M.	CEO	Nov 25 '24	Buy	3.78	14,500	54,868	152,072	Nov 26 07:00 AM
Spoor Johan M.	CEO	Nov 25 '24	Buy	3.80	12,000	45,600	66,600	Nov 26 07:00 AM
Mark Austin	affiliate	Sep 12 '24	Proposed Sale	15.80	2,500	39,500		Sep 12 02:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CATX

Perspective Therapeutics Inc

Upgrade your FINVIZ experience